Executive Director and Global Head, Clinical Operations
Denis Mir joined Grace Science in April 2022 as Executive Director and Global Head, Clinical Operations. Denis brings with him in-depth knowledge of drug development and global clinical research operations in rare diseases and oncology. Throughout his career, Denis has contributed to approvals of two life-changing drugs for cancer patients (Halaven©) and Hemophilia A patients (Roctavian©) as well as several sNDAS.
Prior to joining Grace Science, Denis spent 8 years at BioMarin Pharmaceutical. First, in the UK where he built and grew a successful clinical operations organization that brought key rare disease products to the market. After having successfully established the Hemophilia Gene Therapy Franchise, Denis then moved to BioMarin Headquarter to lead Roctavian registrational phase 3 trials. More recently, Denis also established an Early Pipeline Lead role in the clinical operations organization overseeing early assets entering the clinic for small molecules and gene therapy products. In parallel, he was instrumental in technology adoption for various clinical platform.
Denis Mir received a B.S. in biology and an M.S. in chemistry from University of Sciences in Toulouse, France. He has been member of the American Society of Clinical Oncology (ASCO) since 2002.